A new report maps research into persistent sexual symptoms after SSRIs, finasteride and isotretinoin, with practical questions for a prescriber.
On October 28, 2026, SIDEfxHUB published a research map of university and hospital teams investigating persistent sexual symptoms reported after SSRIs, finasteride and isotretinoin.
The report brings together work on post-SSRI sexual dysfunction (PSSD), post-finasteride syndrome (PFS) and post-Accutane syndrome (PAS). It is an overview of existing research rather than a new clinical trial.
Here are the main lines of work it describes:
Together, these studies ask several different questions: how symptoms are experienced, whether sensory changes can be measured and whether biological differences appear in selected samples. They do not all test the same outcome. Reading them as one continuous chain of proof would blur those distinctions.
In 2022, 37 doctors and researchers from 10 countries proposed diagnostic criteria covering enduring sexual dysfunction after antidepressants, finasteride and isotretinoin. Proposed criteria offer a way to classify reported symptoms; they do not establish a single biological explanation. The report says causes remain unresolved.
The names also do not establish the course of a particular person's symptoms. Persistent symptoms should not be presented as automatically permanent.
An Israeli health-record study cited in the report followed 12,302 men and estimated 1 in 216 among men who used serotonergic antidepressants. That estimate used prescriptions for erectile-dysfunction medication as its definition.
This is a measure of a specific recorded outcome. It does not capture genital numbness and does not address women's experience. The criteria paper cited in the report says incidence is unknown.
The figure should not be treated as a population-wide rate for every persistent sexual symptom or a personalized risk estimate for a gay man over 35.
Small interviews and studies recruited through patient organizations provide accounts of experience. People who come forward may have more severe symptoms, so selected samples do not establish a typical experience. The survey involving sexual and gender minority youth should not be treated as a study of gay men over 35.
Animal findings can inform hypotheses but cannot establish what happens in people. A conference abstract is also not equivalent to a full peer-reviewed paper.
The negative finasteride claims analysis matters. Its underlying trial involved men aged 55 or older and examined specific claims-based outcomes. It should not be generalized to every finasteride user or every possible symptom.
The isotretinoin paper count reflects the search terms used. It is not a comprehensive count of every study relevant to possible sexual effects after isotretinoin.
The report's ClinicalTrials.gov search on October 28, 2026 found no registered treatment trial for the three conditions. That is a dated registry finding, not evidence that every symptom is untreatable or that no treatment research exists anywhere.
For a man over 35, the useful response is a better medication conversation rather than a new longevity ritual. The practical priorities are to discuss sexual effects before decisions are made and seek professional evaluation when symptoms persist.
Caring about hair or skin does not put you at odds with caring about mental health and intimacy. Those priorities deserve a shared discussion instead of an online vote about which concern matters most.
Before starting or changing a medicine, ask the prescriber to discuss known and reported sexual effects alongside the reason for treatment. The report supports making this part of an informed decision rather than deciding from an early study alone.
Useful questions include:
For someone seeking hair-loss treatment, appearance is a legitimate part of the conversation. It need not become a choice framed simply as hair versus sex. The discussion should include the expected benefits of treatment alongside known and reported sexual effects.
That conversation can sit alongside a broader view of body image and sexual wellbeing. Wanting to look attractive and wanting a satisfying sexual life are compatible priorities, not evidence that you are asking too much.
If symptoms continue after a medication has ended, seek a professional evaluation. The proposed criteria discussed in the report include considering whether another medical condition could account for the symptoms.
As a practical record-keeping suggestion, write down what changed and when you noticed it. Note the medication history and whether the concern involves erections, genital sensation or another sexual change. This is a conversation aid rather than a diagnostic test or proof that a medicine caused the symptoms.
A short record should serve the consultation, not become a performance scorecard. There is no need to turn every sexual experience into an informal experiment for the sake of following this story.
A useful starting point is preparing for a sexual-health assessment that gives a clinician a clear account of your concern. Ask what should be evaluated and how follow-up will work rather than trying to match yourself to a syndrome online.
Do not stop an antidepressant abruptly because of a news report. Discuss any medication change with the prescriber.
For the separate question of reporting an isotretinoin side effect, SIDEfxHUB also publishes guidance on reporting side effects. Use reporting information alongside a clinical conversation rather than in place of one.
Sexual wellbeing deserves language that fits your actual life. A discussion can include the kinds of sexual contact that matter to you and the change you have noticed, without assumptions about partners or sexual roles.
There is no need to turn the appointment into a test of masculinity or to defend why sexual sensation matters. A concern about intimacy is a legitimate reason to ask for help whether you are single or partnered.
This also leaves room for confidence beyond a performance score. The aim is a clearer account of your health and a plan discussed with a qualified clinician, not a requirement to be sexually available or perform in a particular way.
Discuss sexual effects before medication decisions, bring persistent changes to qualified care and use the research map to inform questions rather than direct your treatment.
Persistent sexual symptoms deserve more than a medication warning stripped of gay men's social context. GayFitLab's research-led reporting helps men 35+ weigh sexual-health claims within an adult account of appearance and relationships, without reducing gay life to a stereotype or turning medical uncertainty into a promise.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
